Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

Group 1 - Exact Sciences (EXAS) is currently performing well in the Medical sector, with a year-to-date return of approximately 12%, significantly outperforming the sector average of 2% [4] - The Zacks Rank for Exact Sciences is 1 (Strong Buy), indicating a strong potential for outperformance in the market over the next one to three months [3] - The Zacks Consensus Estimate for EXAS' full-year earnings has increased by 134.4% in the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Group 2 - Exact Sciences is part of the Medical - Biomedical and Genetics industry, which consists of 470 companies and currently ranks 87 in the Zacks Industry Rank [6] - The average return for the Medical - Biomedical and Genetics industry so far this year is 9.3%, indicating that Exact Sciences is outperforming its industry peers [6] - Another notable stock in the Medical sector is EssilorLuxottica Unsponsored ADR (ESLOY), which has returned 50.3% year-to-date and also holds a Zacks Rank of 1 (Strong Buy) [5][7]